Xstream Systems, a molecular pharmaceutical authentication company, has entered into a pilot programme with RDC, a member-owned pharmaceutical distribution cooperative.
RDC will test the XT250 Material Identification System, which identifies the exact molecular structure of medication inside an unopened package.
This pilot will determine if the technology can test and identify adulterated or counterfeit products.
In the pilot, RDC will use the XT250 Material Identification System to scan products with a high incidence of counterfeiting.
The XT250 Material Identification System allows non-scientific personnel to test a product without opening the bottle or package it was shipped in.
Xstream Systems will display the data from the pilot programme at an upcoming industry symposium on anti-counterfeiting and anti-diversion strategies.
The pharmaceutical industry has spent millions of dollars over the past few years researching ways to protect the integrity of the supply chain.
